Evidence map›Paper›PMID 39456915›Full record

ArticleInternational journal of molecular sciences2024

Tegaserod Stimulates 5-HT

Christin Hesse, Joachim Neumann, Valerie Compan, Evgeni Ponimaskin, Franziska E Müller, Britt Hofmann, Ulrich Gergs

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Prokinetic drugs that stimulate 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  2. Article
  3. Felcisetrag stimulates 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  4. Bromopride stimulates 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  5. Clebopride stimulates 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christin HesseInstitute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle, Germany.
Joachim NeumannInstitute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle, Germany.
Valerie CompanBrains' Laboratory Lsco, Department of Sciences, Nîmes University, 30021 Nîmes, France.
Evgeni PonimaskinCellular Neurophysiology, Center of Physiology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0002-4570-5130
Franziska E MüllerCellular Neurophysiology, Center of Physiology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0003-0525-0714
Britt HofmannDepartment of Cardiac Surgery, Mid-German Heart Center, University Hospital Halle, 06097 Halle, Germany.
Ulrich GergsInstitute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle, Germany.ORCID 0000-0001-6986-485X

Funding

Deutsche Forschungsgemeinschaft PO732
6 · The paper itself

Abstract

Tegaserod (1-{[(5-methoxy-1H-indol-3-yl)methyliden]amino}-3-pentylguanidine) is a potent agonist at human recombinant 5-HT

Indexed as

Heart AtriaIndolesReceptors, Serotonin, 5-HT4Serotonin 5-HT4 Receptor AgonistsAnimalsCyclic AMPHumansMaleMiceMice, KnockoutMyocardial ContractionCyclic AMPIndolesReceptors, Serotonin, 5-HT4Serotonin 5-HT4 Receptor Agoniststegaserodcardiac serotonin receptorshuman atriummouse atriumtegaserod

Identifiers

PMID39456915
PMCPMC11508481

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.